{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:10:21Z","timestamp":1790511021232,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.leukres.2006.07.005","type":"journal-article","created":{"date-parts":[[2006,9,8]],"date-time":"2006-09-08T19:25:10Z","timestamp":1157743510000},"page":"599-604","source":"Crossref","is-referenced-by-count":166,"title":["Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project"],"prefix":"10.1016","volume":"31","author":[{"given":"June M.","family":"McKoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Angelotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve M.","family":"Trifilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Raisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2006.07.005_bib1","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2006.07.005_bib2","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2006.07.005_bib3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Gemtuzumab ozogamicin therapy is associated with hepatic veno-occlusive disease in patients who have not received stem cell transplantation","volume":"92","author":"Giles","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2006.07.005_bib4","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib5","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1001\/jama.293.17.2131","article-title":"The Research on Adverse Drug Events and Reports (RADAR) project","volume":"293","author":"Bennett","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.leukres.2006.07.005_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3816\/CLM.2002.s.007","article-title":"Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin","volume":"2S","author":"McDonald","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.leukres.2006.07.005_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000046590","article-title":"Hepatic veno-occlusive disease following hematopoietic stem cell transplantation","volume":"106","author":"Richardson","year":"2001","journal-title":"Acta Hemaetol"},{"key":"10.1016\/j.leukres.2006.07.005_bib8","first-page":"1611a","article-title":"Prior allogeneic hematopoietic stem cell transplantation increases the risk of hepatic veno-occlusive disease","volume":"100","author":"Goldberg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib9","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/cncr.11791","article-title":"Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia","volume":"98","author":"Giles","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2006.07.005_bib10","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib11","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"Wadleigh","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00280-002-0546-z","article-title":"Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia","volume":"51","author":"Alvarado","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2006.07.005_bib13","first-page":"3258a","article-title":"Prospective observational study of Mylotarg in usual care: an update","volume":"102","author":"Tallman","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib14","unstructured":"Mylotarg (gemtuzumab ozogamicin for injection). Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2006 [package insert]."},{"key":"10.1016\/j.leukres.2006.07.005_bib15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/annonc\/mdh324","article-title":"Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome\/veno-occlusive disease","volume":"15","author":"Nabhan","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2006.07.005_bib16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2005.05872.x","article-title":"The role of gemtuzumab ozogamicin in acute leukaemia therapy","volume":"132","author":"Tsimberidou","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2006.07.005_bib17","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.leukres.2006.07.005_bib18","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1001\/jama.293.17.2131","article-title":"The Research on Adverse Drug Events and Reports (RADAR) project","volume":"293","author":"Bennett","year":"2005","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.leukres.2006.07.005_bib19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMp048187","article-title":"Expecting the unexpected\u2014drug safety, pharmacovigilance, and the prepared mind","volume":"351","author":"Trontell","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.leukres.2006.07.005_bib20","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jama.294.10.1206-a","article-title":"The RADAR project and the FDA","volume":"294","author":"Trontell","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.leukres.2006.07.005_bib21","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJM200006153422410","article-title":"Thrombotic thrombocytopenic purpura and clopidogrel. A need for new approaches to drug safety","volume":"342","author":"Wood","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2006.07.005_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","article-title":"Gemtuzumab ozogamicin monotherapy for relapsed AML after hemopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease","volume":"30","author":"Cohen","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2006.07.005_bib23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamycin in patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Areci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib24","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0145-2126(03)00021-3","article-title":"Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine, and cyclosporine regimen in patients with refractory acute myelogenous leukemia","volume":"27","author":"Apostolidou","year":"2003","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2006.07.005_bib25","first-page":"341a","article-title":"Gemtuzumab ozogamicin in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age-specific phase 2 trials","volume":"102","author":"DeAngelo","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0145-2126(03)00022-5","article-title":"Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia","volume":"27","author":"Tsimberidou","year":"2003","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2006.07.005_bib27","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/cncr.11239","article-title":"Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2006.07.005_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00280-003-0671-3","article-title":"Mylotarg, fludarabine, cytarabine, and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia","volume":"52","author":"Tsimberidou","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2006.07.005_bib29","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","article-title":"Experience with gemtuzumab ozogamycin and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib30","first-page":"4510a","article-title":"Non-fatal veno-occlusive disease in non-transplant patients after treatment of relapsed AML with gemtuzumab ozogamicin","volume":"99","author":"Langston","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib31","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2002-07-1947","article-title":"Gemtuzumab ozogamicin: first clinical experiences in children with relapsed\/refractory acute myeloid leukemia treated on compassionate-use basis","volume":"101","author":"Zwaan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-002-0539-y","article-title":"Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia","volume":"50","author":"Cortes","year":"2002","journal-title":"Cancer Pharmacol"},{"key":"10.1016\/j.leukres.2006.07.005_bib33","first-page":"3036a","article-title":"Fractionated low-doses of Mylotarg in relapsed AML patients: a pilot study","volume":"100","author":"Castaigne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2006.07.005_bib34","first-page":"2284a","article-title":"Follow-up of gemtuzumab ozogamicin and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"102","author":"Jiang","year":"2003","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212606002669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212606002669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T10:36:18Z","timestamp":1707215778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212606002669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0145212606002669"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2006.07.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}